Were the Kymera Therapeutics (KYMR) share sales by Atlas funds pre-planned?

Yes. A footnote explains the transactions were made under a Rule 10b5-1 trading plan adopted on December 11, 2025. Such plans pre-schedule trades, suggesting these sales were part of a structured program rather than reactive market timing.

How many Kymera Therapeutics (KYMR) shares do the Atlas-related entities still hold after these sales?

The Form 4 shows continuing large indirect positions, including post-transaction holdings of 466,077 shares in one account and 2,603,048 shares in another. These figures indicate that, despite selling, the entities remain significant Kymera shareholders through their funds.

Atlas funds sell 513,245 Kymera (KYMR) shares under 10b5-1 plan

Q: Who actually sold the Kymera Therapeutics (KYMR) shares reported in Bruce Booth’s Form 4?

The shares were sold by investment entities including Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. . Bruce Booth is a member of their general partner entities and disclaims Section 16 beneficial ownership except for any pecuniary interest he may have in these funds.

Q: At what prices were the Kymera Therapeutics (KYMR) shares sold in this Form 4?

Reported weighted-average sale prices include $118.66 , $117.85 , $115.69 , $111.51 , and $105.78 per share. Footnotes note that actual trades occurred in multiple transactions within specified price ranges around each reported average price.

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. director Bruce Booth reported that investment entities associated with him, including Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., sold a combined 513,245 shares of Kymera common stock in open-market transactions.

The sales occurred on June 26 and June 29, 2026 at weighted-average prices such as $118.66 and $105.78 per share, executed under a pre-established Rule 10b5-1 trading plan. The filing shows that these entities continue to hold large indirect positions, including reported post-transaction holdings of 466,077 and 2,603,048 shares.

Insights

VC-affiliated funds sold 513,245 Kymera shares under a 10b5-1 plan while retaining sizable positions.

The filing shows entities linked to director Bruce Booth, notably Atlas Venture Fund X and Atlas Venture Opportunity Fund I, executed 30 open-market sales totaling 513,245 shares of Kymera Therapeutics common stock. Transactions took place on June 26 and June 29, 2026 at weighted-average prices around $105–$119 per share.

A footnote states these trades were made pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025, indicating they were pre-arranged rather than opportunistic. The entities still report large indirect holdings, including positions of 466,077 and 2,603,048 shares after the trades, so the sales represent only part of their exposure.

The pre-planned nature and continued sizable holdings make this look like portfolio management by venture funds rather than a clear signal about Kymera’s near-term prospects. Future company filings may provide additional context on any further asset rebalancing by these holders.

Insider Trade Summary 10b5-1

Net Seller: 513,245 shares ($56,460,136)

Net Sell 30 txns

Insider Booth Bruce

Role null

Sold 513,245 shs ($56.46M)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,471	$105.78	$579K
Sale	Common Stock	14,613	$106.63	$1.56M
Sale	Common Stock	19,093	$107.76	$2.06M
Sale	Common Stock	848	$105.78	$90K
Sale	Common Stock	2,318	$106.63	$247K
Sale	Common Stock	3,024	$107.76	$326K
Sale	Common Stock	28,296	$107.57	$3.04M
Sale	Common Stock	231,007	$108.14	$24.98M
Sale	Common Stock	32,624	$109.79	$3.58M
Sale	Common Stock	11,277	$110.49	$1.25M
Sale	Common Stock	10,366	$111.51	$1.16M
Sale	Common Stock	555	$112.49	$62K
Sale	Common Stock	14,913	$113.97	$1.70M
Sale	Common Stock	27,951	$114.94	$3.21M
Sale	Common Stock	6,821	$115.69	$789K
Sale	Common Stock	12,181	$117.09	$1.43M
Sale	Common Stock	22,046	$117.85	$2.60M
Sale	Common Stock	12,390	$118.66	$1.47M
Sale	Common Stock	3,958	$107.57	$426K
Sale	Common Stock	32,402	$108.14	$3.50M
Sale	Common Stock	4,562	$109.79	$501K
Sale	Common Stock	1,579	$110.49	$174K
Sale	Common Stock	1,442	$111.51	$161K
Sale	Common Stock	78	$112.49	$9K
Sale	Common Stock	2,083	$113.97	$237K
Sale	Common Stock	3,896	$114.94	$448K
Sale	Common Stock	952	$115.69	$110K
Sale	Common Stock	1,701	$117.09	$199K
Sale	Common Stock	3,069	$117.85	$362K
Sale	Common Stock	1,729	$118.66	$205K

Holdings After Transaction: Common Stock — 2,446,453 shares (Indirect, See footnote)

Footnotes (1)

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.995 to $107.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) through (14), and (16) through (18). These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to 108.9725 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.02 to $110.0166 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.02 to $111.0075 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.1057 to $111.9188 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.1843 to $113.0139 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.2614 to $114.246 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.2766 to $115.2672 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.27 to $116.2626 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.2731 to $117.2668 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.2728 to $118.2599 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.2717 to $119.035 inclusive. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive.

Key Figures

Shares sold: 513,245 shares Sample sale price: $118.66 per share Sample sale price: $105.78 per share +3 more

6 metrics

Shares sold 513,245 shares Net open-market sales across 30 transactions on June 26 and 29, 2026

Sample sale price $118.66 per share Open-market sale price on June 26, 2026 for one transaction block

Sample sale price $105.78 per share Open-market sale price on June 29, 2026 for one transaction block

Indirect holding A after trades 466,077 shares Total shares following a June 29, 2026 transaction entry

Indirect holding B after trades 2,603,048 shares Total shares following a June 26, 2026 transaction entry

Number of sale transactions 30 transactions SellCount from transaction summary for this Form 4

Key Terms

Rule 10b5-1 trading plan, weighted average price, Section 16 beneficial ownership, pecuniary interest, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Section 16 beneficial ownership regulatory

"The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities"

pecuniary interest financial

"disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest"

open-market sale financial

"transaction_action":"open-market sale","transaction_code_description":"Sale in open market or private transaction"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 05:30 PM Accepted by SEC EDGAR 06/30/2026 - 05:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Bruce

(Last)

(First)

(Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, FLOOR 4

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/26/2026		S⁽¹⁾		28,296	D	$107.57⁽²⁾	2,834,055	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		231,007	D	$108.14⁽⁴⁾	2,603,048	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		32,624	D	$109.79⁽⁵⁾	2,570,424	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		11,277	D	$110.49⁽⁶⁾	2,559,147	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		10,366	D	$111.51⁽⁷⁾	2,548,781	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		555	D	$112.49⁽⁸⁾	2,548,226	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		14,913	D	$113.97⁽⁹⁾	2,533,313	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		27,951	D	$114.94⁽¹⁰⁾	2,505,362	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		6,821	D	$115.69⁽¹¹⁾	2,498,541	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		12,181	D	$117.09⁽¹²⁾	2,486,360	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		22,046	D	$117.85⁽¹³⁾	2,464,314	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		12,390	D	$118.66⁽¹⁴⁾	2,451,924	I	See footnote⁽³⁾
Common Stock	06/26/2026		S⁽¹⁾		3,958	D	$107.57⁽²⁾	525,760	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		32,402	D	$108.14⁽⁴⁾	493,358	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		4,562	D	$109.79⁽⁵⁾	488,796	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		1,579	D	$110.49⁽⁶⁾	487,217	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		1,442	D	$111.51⁽⁷⁾	485,775	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		78	D	$112.49⁽⁸⁾	485,697	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		2,083	D	$113.97⁽⁹⁾	483,614	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		3,896	D	$114.94⁽¹⁰⁾	479,718	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		952	D	$115.69⁽¹¹⁾	478,766	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		1,701	D	$117.09⁽¹²⁾	477,065	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		3,069	D	$117.85⁽¹³⁾	473,996	I	See footnote⁽¹⁵⁾
Common Stock	06/26/2026		S⁽¹⁾		1,729	D	$118.66⁽¹⁴⁾	472,267	I	See footnote⁽¹⁵⁾
Common Stock	06/29/2026		S⁽¹⁾		5,471	D	$105.78⁽¹⁶⁾	2,446,453	I	See footnote⁽³⁾
Common Stock	06/29/2026		S⁽¹⁾		14,613	D	$106.63⁽¹⁷⁾	2,431,840	I	See footnote⁽³⁾
Common Stock	06/29/2026		S⁽¹⁾		19,093	D	$107.76⁽¹⁸⁾	2,412,747	I	See footnote⁽³⁾
Common Stock	06/29/2026		S⁽¹⁾		848	D	$105.78⁽¹⁶⁾	471,419	I	See footnote⁽¹⁵⁾
Common Stock	06/29/2026		S⁽¹⁾		2,318	D	$106.63⁽¹⁷⁾	469,101	I	See footnote⁽¹⁵⁾
Common Stock	06/29/2026		S⁽¹⁾		3,024	D	$107.76⁽¹⁸⁾	466,077	I	See footnote⁽¹⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.995 to $107.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) through (14), and (16) through (18).

3. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to 108.9725 inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.02 to $110.0166 inclusive.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.02 to $111.0075 inclusive.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.1057 to $111.9188 inclusive.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.1843 to $113.0139 inclusive.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.2614 to $114.246 inclusive.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.2766 to $115.2672 inclusive.

11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.27 to $116.2626 inclusive.

12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.2731 to $117.2668 inclusive.

13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.2728 to $118.2599 inclusive.

14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.2717 to $119.035 inclusive.

15. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.

16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive.

17. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive.

18. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive.

Remarks:

Due to the 30 line limitation in Table I, this report is being filed across two forms. This is the first of two filings.

	/s/ Ommer Chohan, Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

How many Kymera Therapeutics (KYMR) shares were sold in this Form 4 filing?

The filing reports that entities associated with Bruce Booth sold 513,245 shares of Kymera Therapeutics common stock. These sales were executed across 30 open-market transactions on June 26 and June 29, 2026, at various weighted-average prices disclosed in the document.

Who actually sold the Kymera Therapeutics (KYMR) shares reported in Bruce Booth’s Form 4?

The shares were sold by investment entities including Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P.. Bruce Booth is a member of their general partner entities and disclaims Section 16 beneficial ownership except for any pecuniary interest he may have in these funds.

At what prices were the Kymera Therapeutics (KYMR) shares sold in this Form 4?

Reported weighted-average sale prices include $118.66, $117.85, $115.69, $111.51, and $105.78 per share. Footnotes note that actual trades occurred in multiple transactions within specified price ranges around each reported average price.

What does the Form 4 say about Bruce Booth’s beneficial ownership of Kymera (KYMR) shares?

Footnotes state that the securities are held by Atlas venture funds and that Bruce Booth disclaims Section 16 beneficial ownership of these shares, except to the extent of his pecuniary interest, if any, reflecting his role through the funds’ general partner entities.